JPWO2019158658A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019158658A5
JPWO2019158658A5 JP2020542852A JP2020542852A JPWO2019158658A5 JP WO2019158658 A5 JPWO2019158658 A5 JP WO2019158658A5 JP 2020542852 A JP2020542852 A JP 2020542852A JP 2020542852 A JP2020542852 A JP 2020542852A JP WO2019158658 A5 JPWO2019158658 A5 JP WO2019158658A5
Authority
JP
Japan
Prior art keywords
seq
sequence
bone
inhibitor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542852A
Other languages
English (en)
Japanese (ja)
Other versions
JP7395485B2 (ja
JP2021513960A (ja
JP2021513960A5 (https=
Publication date
Priority claimed from GBGB1802486.9A external-priority patent/GB201802486D0/en
Application filed filed Critical
Publication of JP2021513960A publication Critical patent/JP2021513960A/ja
Publication of JPWO2019158658A5 publication Critical patent/JPWO2019158658A5/ja
Publication of JP2021513960A5 publication Critical patent/JP2021513960A5/ja
Application granted granted Critical
Publication of JP7395485B2 publication Critical patent/JP7395485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542852A 2018-02-15 2019-02-14 骨折又は骨欠損の処置のためのグレムリン-1阻害剤 Active JP7395485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1802486.9 2018-02-15
GBGB1802486.9A GB201802486D0 (en) 2018-02-15 2018-02-15 Methods
PCT/EP2019/053726 WO2019158658A1 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect

Publications (4)

Publication Number Publication Date
JP2021513960A JP2021513960A (ja) 2021-06-03
JPWO2019158658A5 true JPWO2019158658A5 (https=) 2022-02-21
JP2021513960A5 JP2021513960A5 (https=) 2022-02-21
JP7395485B2 JP7395485B2 (ja) 2023-12-11

Family

ID=61783877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542852A Active JP7395485B2 (ja) 2018-02-15 2019-02-14 骨折又は骨欠損の処置のためのグレムリン-1阻害剤

Country Status (17)

Country Link
US (2) US11524997B2 (https=)
EP (1) EP3752527A1 (https=)
JP (1) JP7395485B2 (https=)
KR (1) KR20200121833A (https=)
CN (1) CN111683965B (https=)
AR (1) AR114105A1 (https=)
AU (1) AU2019220407B2 (https=)
BR (1) BR112020015961A2 (https=)
CA (1) CA3090404A1 (https=)
CL (2) CL2020002040A1 (https=)
CO (1) CO2020009731A2 (https=)
EA (1) EA202091891A1 (https=)
GB (1) GB201802486D0 (https=)
IL (1) IL276491A (https=)
MX (1) MX2020007431A (https=)
SG (1) SG11202005735SA (https=)
WO (1) WO2019158658A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
PL3806898T3 (pl) 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
EP4511395A1 (en) 2022-04-20 2025-02-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2024244941A1 (en) * 2023-05-26 2024-12-05 The University Of Hong Kong Compositions and methods for the treatment of bone loss
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1053002A1 (en) 1998-02-10 2000-11-22 Oregon Health Sciences University Treatment of bony defects with osteoblast precursor cells
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20120202710A1 (en) 2003-09-09 2012-08-09 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) * 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
JP6339063B2 (ja) 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−1に対する抗体
ES2898620T3 (es) 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
PL3806898T3 (pl) 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu

Similar Documents

Publication Publication Date Title
AU2020277207B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
JP2023002562A5 (https=)
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
JP2021513960A5 (https=)
JP2021521843A5 (https=)
RU2013155906A (ru) Антитела анти-angptl3 и их применение
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2022033868A5 (https=)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2013542194A5 (https=)
JP2025131696A5 (https=)
CN102046199A (zh) 使用抗mif抗体的治疗方法
MX2012014678A (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
JP2017512759A5 (https=)
JP2009511480A5 (https=)
CN103562403A (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
JP2020522280A5 (https=)
JP2020511946A5 (https=)
JP2024024114A5 (https=)
JP2021531732A5 (https=)
JP2021511024A5 (https=)
JPWO2019158658A5 (https=)
JP2025072440A5 (https=)
JP2018529328A5 (https=)
JP2021155416A5 (https=)